MedTrace Logo

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

NCT01108055 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-06-09

Study results available
· View outcomes & findings →

Summary

We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.

Conditions

  • Bladder Cancer
  • Bladder (Urothelial, Transitional Cell) Cancer
  • Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
  • Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
  • Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

Interventions

DRUG

Pazopanib (GW786034)

Cycle of 28 days. Pazopanib: 800mg/day

DRUG

Paclitaxel

Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15

Sponsors & Collaborators

Principal Investigators

  • Dr. Sandy Srinivas · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2015-01-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108055 on ClinicalTrials.gov